Navigation Links
New Cancer Treatment Shrinks Pancreatic Tumor
Date:11/23/2008

NASHVILLE, Tenn., Nov. 24 /PRNewswire/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more weeks of treatment, it no longer could be definitely identified on scans. Pancreatic cancer usually is fatal six to nine months after diagnosis. NeoPlas Innovation's combination of FDA-approved drugs appears to improve those odds for some patients, based on this result and similar ones seen before the protocol's public availability.

The tumor reduction correlated with resolution of the patient's symptoms of pain and digestive problems. "The cancer isn't gone," emphasized NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell. "There are still several metastatic lesions to address, but this kind of response is virtually unheard of in pancreatic cancer. At the very least, we're looking at his having many, many months of added survival with a quality of life he can truly enjoy."

The patient's daughter discussed her father's treatment, saying "He began the NeoPlas treatment after he became too ill to complete his final course of radiation following chemotherapy." She added, "Since then, he has been able to resume work two to three hours a day, go to lunch with other men and even take a ten-day trip to Europe with my brother."

The cholesterol drug Lovastatin is a key part of this treatment that has arrested or eradicated tumors in 78% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 melanoma; he remains disease-free today.

Based on experience and relevant lab research to date, staff members expect the best results for several malignancies. In addition to pancreatic cancer and melanoma, they include colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, cho
'/>"/>

SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
2. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
3. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
4. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
5. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
6. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
7. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
8. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
11. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  IRIDEX Corporation (Nasdaq: IRIX ... year ended January 3, 2015.  , Revenues were ... for the Company and up 11% from $10.6 million in ... also a record, up 12% from $38.3 million in 2013. ... 50.1%, up from 48.6% in the fourth quarter of the ...
(Date:3/5/2015)... March 5, 2015  As the pharmaceutical industry ... Ethics & Compliance professionals are placing a significant ... survey issued today by LRN, the leader in ... overwhelming majority of respondents expressed that clarity on ... component of E&C training programs (57%), trumping understanding ...
(Date:3/5/2015)... CANTEL MEDICAL CORP. (NYSE: CMN ) ... 31, 2015 on Thursday, March 12 before the market opens, ... 11:00 AM ET. To participate in the ... before the beginning of the call. If you are unable ... available from Thursday, March 12, 2015 through midnight on May ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
(Date:3/6/2015)... March 06, 2015 As the Muscular ... services programs, the organization has hired two new Scientific ... They will report to Grace Pavlath, Ph.D, who ... and Scientific Program Director, and together will lead MDA ... treatments and cures for various types of neuromuscular and ...
(Date:3/6/2015)... San Rafael, CA (PRWEB) March 06, 2015 ... the addition of three Maryland camps – two non-contact ... camps will be run by Perfect Performance Training, located ... camps will focus on developing position specific skills, speed ... will be hosted at Salisbury University with Marvin Graves, ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit ... 2015 in Superior Court in the State of California ... of 12 awarded Mrs. Perry $700,000 in actual damages ... Ethicon TVT Abbrevo plastic sling for stress urinary incontinence. ... awarded $5 million in punitive damages. , According to ...
(Date:3/6/2015)... March 06, 2015 Jvion, the ... release of a Clostridium Difficile (C Diff) predictive ... C Diff use case is the latest in ... hospital acquired infections, chronic conditions, and individual illnesses. ... C Diff solution flags at risk individuals to ...
(Date:3/6/2015)... In a new study conducted at a Warsaw hospital, ... pain was their first mesothelioma symptom. Surviving Mesothelioma has just ... to read it now. , Doctors at the Central ... mesothelioma patients between 2006 and 2012 and found ... that first prompted them to see a doctor. For some, ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2
... outbreak of Typhus fever has gripped people in Himachal ... women and children, in Deol area of Baijnath sub-division ... mysterious fever. ,Epidemiologists are suspecting the symptoms to ... typhus', caused by rickettsia, which is spread through bites ...
... study, accepting food cravings and keeping them in check ... ,The first six-month phase of the study provides ... craved, and their role in weight control. ... corresponding author Susan Roberts, PhD, director of the USDA ...
... New Guinea, Maura Elaripe Mea knows the harsh realities of living ... has seen AIDS patients left untreated because doctors feared it would ... not seek help simply because they cannot afford a bus ticket ... eight years ago, the former nurse said the treatment of AIDS ...
... years ago, he lost both hands in a letter bomb explosion. ... motorbike, undeterred by a double hand transplant. ,His ... ,Theo Kelz, a medical wonder with an iron will, was ... from 1993 until his arrest in 1997 with a wave of ...
... gain approval from the Food and Drug Administration (FDA), but ... Wilson Guthrie, a 61-year-old man from Kansas, suffering from end-stage ... with that experimental heart-assist device that keeps his heart pumping. ... cardiothoracic ICU has had, and that a lot of technology ...
... experiencing memory loss are more likely than women without cognitive ... to a study. ,For the study, ... signs of memory problems underwent cognitive tests over 15 years. ... ,The study found the nearly 25 percent of ...
Cached Medicine News:Health News:Weight Management Achieved by Controlling and Not Suppressing Food Cravings 2Health News:Thousands Gather in Sydney for HIV Conference 2Health News:Around the World in 86 Days ... on Motorbike With Double-hand Transplant 2Health News:Around the World in 86 Days ... on Motorbike With Double-hand Transplant 3Health News:US Patient Implanted With HeartMate II, Leaves ICU 2Health News:Older Women With Memory Problems at Increased Risk for Restless Nights 2
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
For the quantitative determination of aspartate aminotransferase in serum. Optimized IFCC procedure without P-5'-P. 500 IU/L at 37C linearity....
The Definitive automated slide stainer is an industry standard. The Definitive allows automated slide staining in a compact, self-contained and easy-to use package....
... an "assembly-line worker" for routine staining protocols ... Programmable continuous slide stainer for routine stains. ... in short time. Its large number of ... working principle provides a high throughput. A ...
Medicine Products: